Skip to content

Detection of Patients With Abnormal Water Distribution Based on Bioelectrical Impedance Analysis (BIA)

Detection of Patients With Abnormal Water Distribution Based on Bioelectrical Impedance Analysis (BIA)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01481311
Enrollment
62
Registered
2011-11-29
Start date
2012-01-31
Completion date
2012-08-31
Last updated
2012-10-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney Diseases

Brief summary

The aim of this clinical investigation is to prove that the seca mbca detects dialysis patients with abnormal water distribution correctly. Abnormal high water distribution is defined as more than 2 liters of Total Body Water (TBW) above a normal value range. TBW and Extra Cellular Water (ECW) are calculated with prediction equations for healthy subjects generated in BCA-01. The results are compared with TBW and ECW ascertained by dilution methods as standard reference methods. The Bioelectrical Impedance Analysis (BIA) method should be evaluated to the accuracy of the absolute measurement of the volume state of dialysis patients (euvolaemic and hypervolaemic) based on a single measurement.

Interventions

DEVICEmedical Body Composition Analyzer seca 514/515

Current of 100 µA

PROCEDUREDeuterium and Sodium Bromide dilution methods

Orally administered to the subject in a solution with 100 ml tap water.

Sponsors

Seca GmbH & Co. Kg.
Lead SponsorINDUSTRY

Study design

Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

The study will cover 50 adults. Men and women in an age range of 18 to 65 years and a Body Mass Index (BMI) range of 18.5 to 35 kg/m2 should be equally distributed. Subjects have to be patients with chronic kidney failure taking dialysis treatment. 25 patients are taken before and another 25 patients after this treatment. Patients that are taken before dialysis treatment should have been dialysed two and not three days before.

Exclusion criteria

* amputation of limbs * gastrointestinal tract illnesses that influence the absorption of substances that are needed for dialysis * bed-ridden patients patients with clinical relevant hypervolaemia or hypovolaemia * electrical implant as cardiac pacemaker * insulin pumps * pregnancy or breastfeeding period * subjects who cannot provide an Informed Consent Form (ICF) by themselves * subjects who might be dependent from the sponsor or the investigation site

Design outcomes

Primary

MeasureTime frameDescription
Bioelectrical impedance (Resistance and Reactance) of 5 and 50 kHz for the right body sideabout 2 minutesThe measurements are utilized as input for prediction equations to calculate TBW and ECW.

Secondary

MeasureTime frameDescription
Bioelectrical impedance (Resistance and Reactance) of 1, 1.5, 2, 3, 7.5, 10, 15, 20, 30, 75, 100, 150, 200, 300, 500, 750 and 1,000 kHzabout 2 minutesThe measurement is planned to be done for all body segments: right arm, left arm, right leg, left leg, trunk, right body side and left body side. In total resistance and reactance at 19 frequencies for 7 body segments are to be measured.
TBWwithin 4 hoursA D2O dose of 400 mg per kg body weight mixed with tap water is administered orally in the morning fasting and after a 2 hour fluid abstention. The distribution of the stable isotope in the TBW is completed after 4 hours. During this period, the subject remains fasting. Two venous blood samples of 10 ml whole blood are taken immediately before and four hours after taking D2O. The plasma samples are analyzed using Isoptopic Ratio Mass Spectrometry (IRMS).
ECWwithin 4 hoursOrally administered NaBr is resorbed quickly and completely and almost exclusively distributes in the extracellular compartment. Blood samples of 10 ml are taken immediately before and 4 hours after oral application of 50 mg NaBr per kg body weight. The serum sample is analyzed by X-Ray Fluorescence Spectroscopy (XRF).

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026